Literature DB >> 18285507

Habituation of premonitory sensations during exposure and response prevention treatment in Tourette's syndrome.

Cara W J Verdellen1, Cees A L Hoogduin, Bernet S Kato, Ger P J Keijsers, Danielle C Cath, Herbert B Hoijtink.   

Abstract

Exposure to premonitory sensations and response prevention of tics (ER) has been shown to be a promising new treatment for Tourette's syndrome (TS). The present study tested the hypothesis that habituation to unpleasant premonitory sensations associated with the tic is an underlying mechanism of change in ER. Patients rated the severity of sensations and urges at 15-minute intervals during ten 2-hour ER sessions. Multilevel models using multiple time trend analyses showed significant reductions of the sensory severity ratings both within and between sessions. The decrease of these severity ratings was related to the frequency of tics exhibited during sessions, regardless of tic severity at baseline. These results support the hypothesis that habituation may be at least part of the underlying working mechanism of exposure in the treatment of tics in TS and that effective tic suppression during sessions is an important factor in this habituation process.

Entities:  

Mesh:

Year:  2008        PMID: 18285507     DOI: 10.1177/0145445507309020

Source DB:  PubMed          Journal:  Behav Modif        ISSN: 0145-4455


  20 in total

Review 1.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

2.  Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II.

Authors:  Christine A Conelea; Michael R Walther; Jennifer B Freeman; Abbe M Garcia; Jeffrey Sapyta; Muniya Khanna; Martin Franklin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-10-02       Impact factor: 8.829

3.  Sensory Phenomena in Tourette Syndrome: Their Role in Symptom Formation and Treatment.

Authors:  David C Houghton; Matthew R Capriotti; Christine A Conelea; Douglas W Woods
Journal:  Curr Dev Disord Rep       Date:  2014-12

4.  The Normal Inhibition of Associations is Impaired by Clonidine in Tourette Syndrome.

Authors:  Ebrahim Kantini; Helen J Cassaday; Chris Hollis; Georgina M Jackson
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-05

Review 5.  Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents.

Authors:  Hannah Weisman; Imraan A Qureshi; James F Leckman; Lawrence Scahill; Michael H Bloch
Journal:  Neurosci Biobehav Rev       Date:  2012-10-23       Impact factor: 8.989

6.  Free will and mental disorder: exploring the relationship.

Authors:  Gerben Meynen
Journal:  Theor Med Bioeth       Date:  2010-12

Review 7.  Clinical assessment of Tourette syndrome and tic disorders.

Authors:  Stephanie C Cohen; James F Leckman; Michael H Bloch
Journal:  Neurosci Biobehav Rev       Date:  2012-12-01       Impact factor: 8.989

8.  Investigating Habituation to Premonitory Urges in Behavior Therapy for Tic Disorders.

Authors:  David C Houghton; Matthew R Capriotti; Lawrence D Scahill; Sabine Wilhelm; Alan L Peterson; John T Walkup; John Piacentini; Douglas W Woods
Journal:  Behav Ther       Date:  2017-08-10

Review 9.  Behavioral therapy for Tourette syndrome and chronic tic disorders.

Authors:  Odette Fründt; Douglas Woods; Christos Ganos
Journal:  Neurol Clin Pract       Date:  2017-04

Review 10.  Neurobiology of the Premonitory Urge in Tourette's Syndrome: Pathophysiology and Treatment Implications.

Authors:  Andrea E Cavanna; Kevin J Black; Mark Hallett; Valerie Voon
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2017-01-25       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.